Awiqli Dose Check

Scroll down

It is for patients with type 2 diabetes who are needing or using selected Novo Nordisk basal insulins,¹including once-weekly Awiqli^®.

_{*To support titration of basal insulin for type 2 diabetes management.}

Dose Check's personalised dose guidance is based on their basal insulin treatment plan and the blood glucose levels and basal insulin doses your patient records.^1,3,4Your patient can set up reminders to record their fasting blood sugar levels and recommended basal insulin doses to help build a routine.¹

You can set up Dose Check for your patients through the Dose Check Dashboard for healthcare professionals via your web or mobile phone browser.⁵

Dose Check can support your patients as they titrate their basal insulin doses at home, and you can check their progress in managing their diabetes remotely through the dashboard.^1,5 You can also gain valuable insights based on your patients' dosing data and fasting blood glucose levels that may support insight-driven personalised treatment decisions.^†1,6

_{^†Based on actual patient behaviour.^1,6}

Supporting patients with Dose Check has been shown to improve glycaemic outcomes,^*,3,4 which may prevent or reduce long-term health complications.^7-10

^*In a single-arm, prospective study, iSage Rx^† produced significant reductions in A1C with low rates of hypoglycaemia, in patients with type 2 diabetes treated solely with detemir, glargine or delgudec insulin.⁴  

_{^†Dose Check is a variant of iSage Rx.³}

Starting basal insulin therapy can feel challenging and overwhelming for many adults with type 2 diabetes,¹¹ and titration may not be prioritised when patients start basal insulin therapy.¹²

71% of adults with type 2 diabetes are yet to reach their HbA_1c target range two years after daily basal insulin initiation.^*13

^*Average baseline HbA_1c 8.6%¹³

72–84% of patients do not recall hearing about titration or dose adjustment from their doctor at their basal insulin initiation visit.¹²

Dose Check is a software developed to assist healthcare professionals and patients in the process of titration for selected Novo Nordisk basal insulins with the follow-up of the responsible healthcare professional. Dose Check does not make any types of diagnoses. It does not substitute the professional medical advice given by doctors, physicians or diabetes care teams.

Any healthcare professional can register free of charge through the Dose Check Dashboard in countries where Dose Check is available. You can access the Dose Check Dashboard via your computer or mobile phone browser.

Dose Check provides guidance for selected Novo Nordisk insulins. Please contact your local Novo Nordisk representative for more information.

Please contact your Novo Nordisk representative to ask if Dose Check is available in your respective country. Healthcare professionals need to register with Dose Check to gain access to the Dose Check Dashboard to set up patients and initiate use.

Novo Nordisk will not have access to data that enables identification of patients registered with Dose Check. All data that may identify a patient such as name, telephone number or date of birth is stored only by the legal manufacturer Amalgam and is not transferred to Novo Nordisk or any third party. For more information about data protection and data privacy, please refer to the Dose Check Privacy Policy.

GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA_1c, glycated haemoglobin.

Data on file: Technical specification document, Dose Check 2.x Device Description

Dose Check Evidence-Based Titration Plans Reference Document.

Clinical Evaluation Report for iSage Rx and Dose Check Software Application (CER-001) Ver. 17.

Grdinovac K et al. Diabetes 2019; 68: 122-LB.

Healthcare Provider User Guide - Dose Check.

UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53.

The Diabetes Control and Complications Trial Research Group. Diabetes 1995; 44(8): 968–83.

Stratton IM et al. BMJ 2000; 321(7258): 405–12.

10.

Russell-Jones D et al. Diabetes Obes Metab 2018; 20(3): 488–496.

11.

Allen NA et al. J Clin Transl Endocrinol 2016; 7: 1–6.

12.

Berard L et al. Diabetes Obes Metab 2018; 20: 301–308.

13.

Curtis B, Lage MJ. J Med Econ 2014;17:1, 21–31.

Dose Check is CE marked. Notified body 2862. Dose Check is certified against the EU Medical Device Regulations (MDR) 2017/745.
Manufacturer: Amalgam Rx, Inc. 1007 N. Orange St, Ste. 400, Wilmington, DE 19801, USA Authorised Representative: Medical Device Safety Service GmbH, Schiffgraben 41, 30175 Hannover, Germany.

Dose Check is available in a number of countries and additional launches are planned in the near future. Time frames will vary according to device, insulin brand and unique market regulations. Dose guidance apps and the information contained in these materials are not intended as a substitute for professional medical advice.

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

The Summary of Product Characteristics (SmPC) is based on the EU SmPC as of May 2024. Registration conditions differ internationally. Always refer to the full local SmPC before prescribing.

HQ24DC00030, August 2024

For healthcare professionals only